Sandoz secures US FDA approval for long-acting biosimilar Ziextenzo
Ziextenzo is approved for treating patients with non-myeloid malignancies, under myelosuppressive anti-cancer drugs, and with an incidence of…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 Nov 19
Ziextenzo is approved for treating patients with non-myeloid malignancies, under myelosuppressive anti-cancer drugs, and with an incidence of…
04 Nov 19
The results from EXCEED demonstrated a consistent and favourable safety profile for Cosentyx and no new safety signals…
01 Nov 19
BeiGene will commercialise Amgen’s Xgeva, Kyprolis and Blincyto in China for five or seven years, for equal share…
31 Oct 19
The EMA has granted Accelerated Assessment, and the Committee for Medicinal Products for Human Use (CHMP) is currently…
30 Oct 19
The Phase III POSEIDON trial has reached a primary endpoint of statistically significant and clinically meaningful improvement in…
29 Oct 19
The clinical programme involves two studies, namely EAGLE-1, and EAGLE-2, and is conducted by the centres for disease…
29 Oct 19
The EC approval for the combination treatment is based on the Phase III JAVELIN Renal 101 study, which…
28 Oct 19
Astellas has secured the US and Japan regulatory approvals in 2018 for gilteritinib for the treatment of patients…
25 Oct 19
Cosentyx is supported by sufficient clinical evidence, including 5-year data across PsO, PsA and AS, along with data…
About 2,000 people die in the UK each year from taking powerful painkillers - and overprescriptions are a…